This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

HomeBrowseAboutFAQs
Log In
Sign Up
Idiopathic Pulmonary Fibrosis

Phase 2a Evaluation of PLN-74809 on αvβ6 Receptor Occupancy Using PET Imaging in Participants With IPF/

Sponsored by Pliant Therapeutics, Inc.

About this trial

Last updated 3 years ago

Study ID

PLN-74809-IPF-201

Status

Completed

Type

Interventional

Phase

Phase 2

Placebo

No

Accepting

18-75 Years
40+ Years
All
All

Not accepting

Not accepting
Healthy Volunteers

Trial Timing

Ended 3 years ago

What is this trial about?

A study in mild/moderate IPF patients using an αVβ6 PET ligand to evaluate target engagement.

What are the participation requirements?

Yes

Inclusion Criteria

- Diagnosis of IPF, within 5 years prior to Screening,

- FVC %predicted ≥45%; historical FVC for entry in the study is permitted if within 1 month of screening.

- DLco (hemoglobin-adjusted) ≥30%; historical DLco for entry in the study is permitted if within 1 month of screening.

- Participants receiving treatment for IPF with nintedanib or pirfenidone are allowed,if on a stable dose for at least 3 months

No

Exclusion Criteria

- Currently receiving or planning to initiate treatment for IPF (fibrosis) with agents not approved for that indication by the FDA

- Forced expiratory volume during the first seconds of the forced breath (FEV1)/FVC ratio <0.7

- Clinical evidence of active infection, including but not limited to bronchitis, pneumonia, sinusitis that can affect FVC measurement or IPF progression

- Known acute IPF exacerbation or suspicion by the Investigator of such, within 6 months of Screening

- Smoking of any kind within 3 months of Screening